Abstract
T-cell activation is dependent on signals delivered through the antigen-specific T-cell receptor and accessory receptors on T-cells. Integration of signals through this family of costimulatory and inhibitory receptors and their ligands regulates the balance between T-cell activation, tolerance, and immunopathology. Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals and exert a vital and diverse range of immunoregulatory roles in T-cell activation, tolerance, and immune-mediated tissue damage. In this review, we revisit current understanding of the immunoregulatory functions of PD-1 and its ligands and their involvement in immune-mediated diseases.
Keywords: Alzheimer's disease, autoimmunity, costimulation, HIV infection, immune tolerance, multiple sclerosis, PD-1, PD-L1, T-cell activation, immune system, microbial pathogens, antigens, antigenic peptide/major histocompatibility complex, costimulatory signals, phenotype
Current Molecular Medicine
Title: The PD-1/PD-L1 Pathway in Human Pathology
Volume: 12 Issue: 3
Author(s): M. Saresella, V. Rainone, N. M. Al-Daghri, M. Clerici and D. Trabattoni
Affiliation:
Keywords: Alzheimer's disease, autoimmunity, costimulation, HIV infection, immune tolerance, multiple sclerosis, PD-1, PD-L1, T-cell activation, immune system, microbial pathogens, antigens, antigenic peptide/major histocompatibility complex, costimulatory signals, phenotype
Abstract: T-cell activation is dependent on signals delivered through the antigen-specific T-cell receptor and accessory receptors on T-cells. Integration of signals through this family of costimulatory and inhibitory receptors and their ligands regulates the balance between T-cell activation, tolerance, and immunopathology. Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals and exert a vital and diverse range of immunoregulatory roles in T-cell activation, tolerance, and immune-mediated tissue damage. In this review, we revisit current understanding of the immunoregulatory functions of PD-1 and its ligands and their involvement in immune-mediated diseases.
Export Options
About this article
Cite this article as:
Saresella M., Rainone V., M. Al-Daghri N., Clerici M. and Trabattoni D., The PD-1/PD-L1 Pathway in Human Pathology, Current Molecular Medicine 2012; 12 (3) . https://dx.doi.org/10.2174/156652412799218903
DOI https://dx.doi.org/10.2174/156652412799218903 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug
Current Pharmaceutical Design Overactive Bladder Symptoms in Patients with Fibromyalgia: A Systematic Case-Controlled Study
Reviews on Recent Clinical Trials Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology New Drugs for Immune Targeting
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Viruses and Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Chondroitin Sulfate, a Major Niche Substance of Neural Stem Cells, and Cell Transplantation Therapy of Neurodegeneration Combined with Niche Modification
Current Stem Cell Research & Therapy Targeting the Chemokine Receptor CXCR3 and Its Ligand CXCL10 in the Central Nervous System: Potential Therapy for Inflammatory Demyelinating Disease?
Current Neurovascular Research Daidzein and its Effects on Brain
Current Medicinal Chemistry Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design Matrix Metalloproteinase-9/Gelatinase B is a Putative Therapeutic Target of Chronic Obstructive Pulmonary Disease and Multiple Sclerosis
Current Pharmaceutical Biotechnology The Role of Regulatory T Cells in Contact Hypersensitivity
Recent Patents on Inflammation & Allergy Drug Discovery IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression
Current Drug Targets Targeting Cancer Stem Cells as a Therapeutic Approach in Liver Cancer
Current Gene Therapy Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery BAFFling Autoimmune Disorders and Helicobacter pylori Disease: The Interplay between BAFF and the Th17 Response
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) The Biochemical Mechanisms of T-Cell Anergy
Current Immunology Reviews (Discontinued) A Current Understanding of Ocular Immune Privilege
Current Immunology Reviews (Discontinued) Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry A Possible Role for Interleukin 37 in the Pathogenesis of Behcet's Disease
Current Molecular Medicine